Sage Journals: Discover world-class research

Abstract

Objective:

To study factors that influence the concentration of cell-free fetal DNA (fetal fraction) using a large clinical data set of pregnancies with male fetus.

Method:

A retrospective analysis of 23 067 pregnancies that received noninvasive prenatal testing from January 2012 to October 2013, including 22 650 normal singleton pregnancies (control group) and 417 pregnancies with aneuploidy, twin pregnancy, or various maternal conditions including preexisting hypertension, preexisting diabetes, hyperthyroidism, and carrier of the surface antigen of the hepatitis B virus (HBsAg; study group). Multiples of the median (MoM) analysis was performed in the control group to derive gestation and body mass index (BMI)-corrected fetal fraction. The effects of study group conditions on fetal fraction were examined by calculating the ratio of MoM (RMoM) values.

Results:

Fetal fraction showed a positive correlation with gestational age (r² = .10, P < .001) and increased rapidly after the 21 weeks of gestation (r² = .26, P < .001). Negative association with maternal BMI was found with fetal fraction (r² = .04, P < .001). In study group, fetal fraction was higher among pregnant women with a trisomy 21 fetus (RMoM = 1.24, P < .001) and lower among trisomy 18 (RMoM = 0.84, P < .001). A 1.6-fold incensement of fetal fraction was observed in twin fetuses comparing to singleton pregnancy (RMoM = 1.62, P < .001). Women with preexisting hypertension had significantly lower fetal fraction (RMoM = 0.85, P = .02). Preexisting diabetes, hyperthyroidism, or carrier of HBsAg did not affect fetal fraction.

Conclusion:

The fetal fraction was affected by fetal aneuploidy, maternal BMI, and the number of gestation. Maternal preexisting of hypertension appeared to reduce fetal fraction.

Keywords

fetal fraction gestational age body mass index preexisting hypertension twin pregnancy multiples of the median.

Get full access to this article

View all access options for this article.

References

Corbetta

Chamberlain

. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–487.

Sikora

Zimmermann

Rusterholz

. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem. 2010;56(1):136–138.

Wang

Batey

Struble

Musci

Song

Oliphant

. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662–666.

Wataganara

Peter

Messerlian

Borgatta

Bianchi

. Inverse correlation between maternal weight and second trimester circulating cell-free fetal DNA levels. Obstet Gynecol. 2004;104(3):545–550.

Alberry

Maddocks

Hadi

. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol. 2009;200(1):98.e1–98.e6.

Levine

Qian

Leshane

. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190(3):707–713.

Al Nakib

Desbrière

Bonello

. Total and fetal cell-free DNA analysis in maternal blood as markers of placental insufficiency in intrauterine growth restriction. Fetal Diagn Ther. 2009;26(1):24–28.

Ashoor

Poon

Syngelaki

Mosimann

Nicolaides

. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: effect of maternal and fetal factors. Fetal Diagn Ther. 2012;31(4):237–243.

Lapaire

Volgmann

Huang

Hahn

Holzgreve

Zhong

. Maternal smoking: effect on circulating cell-free fetal and total DNA levels in maternal plasma from the second trimester. Obstet Gynecol. 2007;110(6):1358–1363.

10.

Pan

Peter

Lambert-Messerlian

Canick

Bianchi

Johnson

. Cell-free fetal DNA levels in pregnancies conceived by IVF. Hum Reprod. 2005;20(11):3152–3156.

11.

Lee

LeShane

Messerlian

. Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol. 2002;187(5):1217–1221.

12.

Farina

LeShane

Lambert-Messerlian

. Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. Clin Chem. 2003;49(2):239–242.

13.

Gerovassili

Garner

Nicolaides

Thein

Rees

. Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities? Prenat Diagn. 2007;27(2):104–110.

14.

Rava

Srinivasan

Sehnert

Bianchi

. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem. 2014;60(1):243–250.

15.

Pergament

Cuckle

Zimmermann

. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014;124(2 pt 1):210–218.

16.

Dar

Curnow

Gross

. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol. 2014;211(5):527.e1–527.e17.

17.

Jiang

Ren

Chen

. Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics. 2012;5:57.

18.

Dan

Wang

Ren

. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn. 2012;32(13):1225–1232.

19.

Bianchi

. Circulating fetal DNA: its origin and diagnostic potential—a review. Placenta, 2004;25(suppl A):S93–S101.

20.

Benn

Borell

Chiu

. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2013;33(7):622–629.

21.

Wataganara

LeShane

Farina

. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet. 2003;112(2):204–208.

22.

Ashoor

Syngelaki

Poon

Rezende

Nicolaides

. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26–32.

23.

Baty

Blackburn

Carey

. Natural history of trisomy 18 and trisomy 13: I. Growth, physical assessment, medical histories, survival, and recurrence risk. Am J Med Genet. 1994;49(2):175–188.

24.

Hahn

Rusterholz

Hösli

Lapaire

. Cell-free nucleic acids as potential markers for preeclampsia. Placenta. 2011;32(suppl):S17–S20.

25.

Knight

Redman

Linton

Sargent

. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1998;105(6):632–640.

26.

Slonim

Koide

Johnson

. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci USA. 2009;106(23):9425–9429.

27.

Muchova

Zitnanova

Durackova

. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy? Physiol Res. 2014;63(5):535–542.

28.

Porreco

Garite

Maurel

. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014;211(4):365.e1–365.e12.

29.

Norton

Brar

Weiss

. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol, 2012;207(2):137.e1–137.e8.

30.

Ashoor

Syngelaki

Wagner

Birdir

Nicolaides

. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):322.e1–322.e5.

31.

Bianchi

Platt

Goldberg

. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890–901.

32.

Lenfant

Chobanian

Jones

Roccella

; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41(6):1178–1179.

33.

Salmani

Purushothaman

Somashekara

. Study of structural changes in placenta in pregnancy-induced hypertension. J Nat Sci Biol Med. 2014;5(2):352–355.

34.

Bzowej

. Hepatitis B therapy in pregnancy. Curr Hepat Rep. 2010;9(4):197–204.

35.

Glinoer

Soto

Bourdoux

. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991;73(2):421–427.

36.

Kelly

Evans

Messenger

. Controversies around gestational diabetes. Practical information for family doctors. Can Fam Phys. 2005;51:688–695.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.04 MB

0.08 MB

0.03 MB

Effects of Maternal and Fetal Characteristics on Cell-Free Fetal DNA Fraction in Maternal Plasma

Abstract

Objective:

Method:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material